Cancer in the time of COVID-19: expert opinion on how to adapt current practice

Eur Respir J. 2020 May 14;55(5):2000959. doi: 10.1183/13993003.00959-2020. Print 2020 May.

Abstract

Our current thoracic oncology practice could/should be adapted to the COVID-19 pandemic by reducing time in hospital and patient contacts with healthcare workers, whilst maintaining quality of care. This letter offers expert advice on how to do so. https://bit.ly/2JR2IoT

Publication types

  • Letter

MeSH terms

  • Belgium
  • COVID-19
  • Carcinoma, Non-Small-Cell Lung / drug therapy
  • Carcinoma, Non-Small-Cell Lung / radiotherapy
  • Carcinoma, Non-Small-Cell Lung / surgery
  • Coronavirus Infections / epidemiology*
  • Disease Susceptibility
  • France
  • Humans
  • Lung Neoplasms / drug therapy
  • Mesothelioma / drug therapy
  • Mesothelioma, Malignant
  • Neoplasms / drug therapy
  • Neoplasms / radiotherapy
  • Neoplasms / surgery
  • Neoplasms / therapy*
  • Neoplasms, Glandular and Epithelial / drug therapy
  • Pandemics
  • Pneumonia, Viral / epidemiology*
  • Practice Guidelines as Topic
  • Prognosis
  • Small Cell Lung Carcinoma / drug therapy
  • Small Cell Lung Carcinoma / radiotherapy
  • Societies, Medical
  • Telemedicine
  • Thymus Neoplasms / drug therapy
  • United Kingdom
  • Videoconferencing

Supplementary concepts

  • Thymic epithelial tumor